View Older Stories View More Recent Stories

Dec 31, 2025 06:55AM Axsome receives FDA feedback supporting AXS-12 narcolepsy drug filing
Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026
Nov 6, 2025 07:02AM Axsome Therapeutics acquires epilepsy drug candidate from AstraZeneca
Nov 6, 2025 07:01AM Axsome acquires Avenue's subsidiary for epilepsy drug development
Nov 3, 2025 04:51PM Axsome Therapeutics (AXSM) files mixed shelf
Nov 3, 2025 02:39PM Axsome Therapeutics (AXSM) PT Raised to $205 at Guggenheim
Nov 3, 2025 07:11AM Axsome Therapeutics (AXSM) Misses Q3 EPS by 10c
Oct 1, 2025 02:51AM B.Riley Starts Axsome Therapeutics (AXSM) at Buy
Sep 17, 2025 07:32AM Piper Sandler Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
Sep 16, 2025 07:19AM Cantor Fitzgerald Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
Sep 10, 2025 09:16AM RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
Sep 3, 2025 02:41AM Wells Fargo Assumes Axsome Therapeutics (AXSM) at Overweight
Aug 22, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Aug 21, 2025 06:16AM Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
Aug 20, 2025 09:36AM Axsome Therapeutics (AXSM) Stock Has 45% Upside, per RBC Capital
Aug 4, 2025 07:34AM Axsome Therapeutics (AXSM) Tops Q2 EPS by 9c
Jul 22, 2025 07:28AM Cantor Fitzgerald Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
Jul 22, 2025 06:38AM Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
Jul 18, 2025 09:58AM Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
Jul 7, 2025 07:02AM Axsome to host brain health R&D event on July 21 in New York
Jul 3, 2025 06:39AM Morgan Stanley Assumes Axsome Therapeutics (AXSM) at Overweight
Jun 10, 2025 09:24AM Piper Sandler Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
Jun 10, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Jun 9, 2025 11:54AM Axsome Therapeutics (AXSM) PT Lowered to $183 at Oppenheimer
Jun 9, 2025 07:02AM Axsome Therapeutics (AXSM) Provides Update on the New Drug Application for AXS-14
Jun 3, 2025 08:14AM Oppenheimer Starts Axsome Therapeutics (AXSM) at Outperform
Jun 2, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
May 27, 2025 07:01AM Axsome Therapeutics (AXSM) Settles SUNOSI Patent Litigation with Hetero Labs
May 13, 2025 07:02AM Axsome Therapeutics (AXSM) Enters $570M Term Loan and Revolving Credit Facility with Blackstone
May 7, 2025 07:16AM Axsome Therapeutics (AXSM) PT Lowered to $180 at H.C. Wainwright
May 6, 2025 05:39AM Axsome Therapeutics (AXSM) PT Raised to $176 at BofA Securities
May 5, 2025 07:14AM Axsome Therapeutics (AXSM) Tops Q1 EPS by 8c
Apr 29, 2025 06:43AM Axsome Therapeutics (AXSM) PT Raised to $193 at RBC Capital
Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets
Apr 11, 2025 09:44AM Piper Sandler: 'What Biotech Names to Own in Market Volatility'
Apr 7, 2025 02:31AM Jefferies Starts Axsome Therapeutics (AXSM) at Buy
Apr 4, 2025 07:00AM Axsome Therapeutics (AXSM) Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05
Apr 2, 2025 10:29AM Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
Apr 1, 2025 10:07AM Mizuho on Axsome Therapeutics (AXSM): 'we recommend being opportunistic on any continued weakness'
Apr 1, 2025 10:06AM Guggenheim on Axsome Therapeutics (AXSM): 'This does not come as a surprise to us'
Apr 1, 2025 10:05AM BofA on Axsome Therapeutics (AXSM): 'post IP resolution we expect Axsome shares to benefit from scarcity value of high growth'
Apr 1, 2025 07:00AM Axsome Therapeutics (AXSM) Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol
Mar 26, 2025 09:27AM Piper Sandler Reiterates Overweight on Axsome Therapeutics (AXSM) Following FOCUS Results
Mar 26, 2025 08:09AM Axsome Therapeutics (AXSM) PT Raised to $216 at Mizuho
Mar 25, 2025 12:20PM Guggenheim Defending Axsome Therapeutics (AXSM), 'buyers of AXSM shares on today's weakness'
Mar 25, 2025 07:00AM Axsome Therapeutics (AXSM) Announces FOCUS Phase 3 Trial of Solriamfetol Achieves Primary Endpoint
Mar 15, 2025 04:00PM Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
Mar 13, 2025 06:58AM Cantor Biotech industry report, buying value in RevGens
Mar 11, 2025 08:30AM Piper Sandler 'Staying Bullish' on Axsome Therapeutics (AXSM)
Mar 6, 2025 06:54AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
View More Recent Stories View Older Stories